Cargando…
Inactivation of SARS‐CoV‐2 and HCoV‐229E in vitro by ColdZyme® a medical device mouth spray against the common cold
BACKGROUND: The coronavirus disease 2019 (COVID‐19) pandemic calls for effective and safe treatments. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) causing COVID‐19 actively replicates in the throat, unlike SARS‐CoV, and shows high pharyngeal viral shedding even in patients with mild...
Autores principales: | Gudmundsdottir, Ágústa, Scheving, Reynir, Lindberg, Fredrik, Stefansson, Bjarki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537187/ https://www.ncbi.nlm.nih.gov/pubmed/32975843 http://dx.doi.org/10.1002/jmv.26554 |
Ejemplares similares
-
Early intervention with ColdZyme mouth spray after self-diagnosis of common cold: A randomized, double-blind, placebo-controlled study
por: Lindberg, B. Fredrik, et al.
Publicado: (2023) -
ColdZyme Maintains Integrity in SARS-CoV-2-Infected Airway Epithelia
por: Posch, W., et al.
Publicado: (2021) -
Evaluation of ColdZyme® Mouth Spray on prevention of upper respiratory tract infections in a boy with primary immunodeficiency: a case report
por: Clarsund, Mats, et al.
Publicado: (2016) -
ColdZyme® protects airway epithelia from infection with BA.4/5
por: Viktoria, Zaderer, et al.
Publicado: (2022) -
Biochemical characterization of a native group III trypsin ZT from Atlantic cod (Gadus morhua)
por: Sandholt, Gunnar B., et al.
Publicado: (2019)